Combination of TATE and PD-1 Inhibitor in Liver Cancer

Status: active

This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular carcinoma (HCC),and metastatic gastric cancer. All enrolled patients need to have liver lesions and have progressed on a prior immune checkpoint inhibitor.

Inclusion Criteria

1. Patients with a confirmed diagnosis of (1) advanced HCC or (2) metastatic gastric cancer. 2. Patients between ages 18 and 80 3. If HCC patients, they should have progressive disease (PD) on an immune therapy for advanced HCC. For patients with metastatic gastric cancer, they should have failed at least one line of systemic chemotherapy and an immune checkpoint inhibitor. 4. Patients with liver tumor lesions with at least one with a diameter of 2 cm or bigger, which is amendable for (super-)selective TATE as the target lesion. 5. ECOG score 2 or less 6. Child-Pugh scores 5-7 for HCC patients 7. All prior chemotherapy at least 4 weeks prior to study treatment. Immunotherapy not subject to this limitation. 8. No major GI bleeding in the prior 2 months. 8. Hgb>=8, platelet >= 50,000, Cr =< 2, AST and ALT < 10 X ULN, t-Bilirubin < 3, 9. Patients with a history of major autoimmune disorders excluded.

Additional locations may be listed on ClinicalTrials.gov for NCT03259867.

State:

United States

California

Orange

UC Irvine Health/Chao Family Comprehensive Cancer Center

Status: Active

Contact: Jennifer D. Berg

Phone: 714-456-7687

Email: jdberg@uci.edu

Oklahoma

Oklahoma City

University of Oklahoma Health Sciences Center

Status: Active

Name Not Available

The goal of the study is to investigate whether tumor necrosis induced by Trans-arterial

Tirapazamine Embolization (TATE) treatment can boost anti-tumor immunity and enhance the

therapeutic efficacy of immune checkpoint inhibitor. Patients with advanced liver cancers

(primary HCC or metastatic gastric cancer) who have progressed on a prior immune

checkpoint inhibitor will be enrolled in the study. Liver lesions will be treated with up

to 4 TATE treatments for optimal debulking, which also serve as a vaccination process

toward tumor. Lesion not treated with TATE will be used for monitoring the response

toward a PD-1 inhibitor (Nivolumab) for abscopal effect. If a patient subsequently

develops an "escape" to the PD-1 inhibitor, patient can have another 2 TATE treatments of

the escaped tumor lesion. Dosing of the PD-1 inhibitor is per standard FDA-approved

dosing schedule and continues until progressive disease. The efficacy will be assessed by

the response rate (RR) using RECIST.

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.

Combination of TATE and PD-1 Inhibitor in Liver Cancer

Description

Eligibility Criteria

Locations & Contacts

Trial Objectives and Outline

Trial Phase & Type

Lead Organization

Trial IDs

Have a question?We're here to help

Which trials are right for you?

Have a question?
We're here to help